These highlights do not include all the information needed to use KEVEYIS® safely and effectively. See full prescribing information for KEVEYIS®. KEVEYIS® (dichlorphenamide) tablets, for oral use Initial U.S. Approval: 1958

These highlights do not include all the information needed to use KEVEYIS® safely and effectively. See full prescribing information for KEVEYIS®. KEVEYIS® (dichlorphenamide) tablets, for oral use Initial U.S. Approval: 1958

Drug Labeling and Warnings

Drug Details

k">

KEVEYIS- dichlorphenamide tablet 
Strongbridge US Inc.

----------

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use KEVEYIS® safely and effectively. See full prescribing information for KEVEYIS®.

KEVEYIS® (dichlorphenamide) tablets, for oral use
Initial U.S. Approval: 1958

RECENT MAJOR CHANGES

Dosage and Administration (2.1, 2.3)11/2019
Warnings and Precautions (5.2, 5.3, 5.4)11/2019

INDICATIONS AND USAGE

KEVEYIS is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants (1)

DOSAGE AND ADMINISTRATION

  • Initate dosing at 50 mg by mouth once or twice daily (2.1)
  • Titrate up or down dose based on individual response (2.1)
  • The minimum recommended dosage is 50 mg daily, and the maximum recommended dosage is 200 mg daily (2.1)
  • Evaluate response to KEVEYIS after 2 months of treatment (2.2)

DOSAGE FORMS AND STRENGTHS

Tablets: 50 mg (3)

CONTRAINDICATIONS

  • Hepatic insufficiency (4)
  • Severe pulmonary obstruction (4)
  • Hypersensitivity to dichlorphenamide or other sulfonamides (4)
  • Concomitant use with high dose aspirin (4)

WARNINGS AND PRECAUTIONS

  • Hypersensitivity and Other Life-Threatening Reactions: discontinue KEVEYIS at the first appearance of skin rash or any sign of immune-mediated or idiosyncratic adverse reaction (5.1)
  • Hypokalemia: baseline and periodic measurements of serum potassium are recommended; if hypokalemia develops or persists, consider reducing the dose or discontinuing KEVEYIS and correcting potassium levels (5.3)
  • Metabolic acidosis: baseline and periodic measurements of serum bicarbonate are recommended; if metabolic acidosis develops or persists, consider reducing the dose or discontinuing KEVEYIS (5.4)
  • Falls: consider reducing the dose or discontinuing KEVEYIS in patients who experience falls (5.5)

ADVERSE REACTIONS

Most common adverse reactions (incidence at least 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Strongbridge Biopharma at 1-855-324-8912, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Aspirin: anorexia, tachypnea, lethargy, and coma have been reported with concomitant use of dichlorphenamide and high-dose aspirin. The concomitant use of KEVEYIS and high dose aspirin is contraindicated. KEVEYIS should be used with caution in patients receiving lower doses of aspirin (4, 5.2, 7.1)

USE IN SPECIFIC POPULATIONS

Pregnancy: Based on animal data, may cause fetal harm (8.1)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 11/2019

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.

2 DOSAGE AND ADMINISTRATION

2.1 Dosage Information

Initiate dosing at 50 mg by mouth once or twice daily. The dosage may be increased or decreased based on individual response, at weekly intervals (or sooner in case of adverse reaction). The minimum recommended total daily dosage is 50 mg, and the maximum recommended total daily dosage is 200 mg.

2.2 Monitoring to Assess Effectiveness

Primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants are a heterogeneous group of conditions, for which the response to KEVEYIS may vary. Therefore, prescribers should evaluate the patient's response to KEVEYIS after 2 months of treatment to decide whether KEVEYIS should be continued.

2.3 Monitoring to Assess Safety

Baseline and periodic measurements of serum potassium and sodium bicarbonate during KEVEYIS treatment is recommended [see Warnings and Precautions (5.3, 5.4)].

3 DOSAGE FORMS AND STRENGTHS

Round, white tablets, scored on one side, engraved with "D" above the score and "50" below the score, the other side is plain, 50 mg each.

4 CONTRAINDICATIONS

KEVEYIS is contraindicated in the following circumstances:

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity and Other Life-Threatening Reactions

Fatalities associated with the administration of sulfonamides have occurred because of adverse reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias. Pulmonary involvement can occur in isolation or as part of a systemic reaction.

KEVEYIS should be discontinued at the first appearance of skin rash or any sign of immune-mediated or other life-threatening adverse reaction.

5.2 Concomitant Use of Aspirin or Other Salicylates

Carbonic anhydrase inhibitors, including KEVEYIS, can cause metabolic acidosis [see Warnings and Precautions (5.4)], which can increase the risk of salicylate toxicity.   Anorexia, tachypnea, lethargy, and coma have been reported with concomitant use of dichlorphenamide and high-dose aspirin. Therefore, the concomitant use of KEVEYIS and high-dose aspirin is contraindicated. Patients with concomitant use of KEVEYIS and low-dose aspirin should be carefully monitored.

5.3 Hypokalemia

KEVEYIS increases potassium excretion and can cause hypokalemia.  The risk of hypokalemia is greater when KEVEYIS is used in patients with conditions associated with hypokalemia (e.g., adrenocortical excess, renal tubular acidosis type 1 and 2), and in patients receiving other drugs that may cause hypokalemia [see Drug Interactions (7.3)].

Baseline and periodic measurements of serum potassium during KEVEYIS treatment is recommended.

If hypokalemia develops or persists, consideration should be given to reducing the dose or discontinuing KEVEYIS and correction of potassium levels.

5.4 Metabolic Acidosis

KEVEYIS can cause hyperchloremic non-anion gap metabolic acidosis. Concomitant use of KEVEYIS with other drugs that cause metabolic acidosis may increase the severity of acidosis. Concomitant use of KEVEYIS in compensated patients with respiratory acidosis, such as in advanced lung diseases, may lead to respiratory decompensation.

Baseline and periodic measurements of serum bicarbonate during KEVEYIS treatment are recommended.

If metabolic acidosis develops or persists, consideration should be given to reducing the dose or discontinuing KEVEYIS [see Drug Interactions (7.4)].

5.5 Falls

KEVEYIS increases the risk of falls. The risk of falls is greater in the elderly and with higher doses of KEVEYIS. Consider dose reduction or discontinuation of KEVEYIS in patients who experience falls while treated with KEVEYIS.

6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in labeling:

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In a 9-week randomized controlled trial in adults with hyperkalemic or hypokalemic periodic paralysis (Study 1), the most common adverse reactions in patients treated with KEVEYIS, with rates greater than placebo, were paresthesia, cognitive disorder, dysgeusia, and confusional state. The mean dose of KEVEYIS was 94 mg/day in patients with hypokalemic periodic paralysis and 82 mg/day in patients with hyperkalemic periodic paralysis.

Table 1 lists the incidence of adverse reactions that occurred in ≥ 5% of patients treated with KEVEYIS and more commonly than in patients treated with placebo in Study 1.

Table 1: Adverse Reactions in Patients Treated with KEVEYIS with Incidence ≥ 5% and more common than in Patients Treated with Placebo in Study 1
Adverse ReactionKEVEYIS
N = 36
(%)
Placebo
N = 29
(%)
  • * Cognitive disorder combined cases with the preferred terms of cognitive disorder, disturbance in attention, and mental impairment.
  • Nervous system disordersParesthesia4414
    Cognitive disorder*147
    Dysgeusia140
    Confusional state110
    Headache87
    Hypoesthesia80
    Lethargy80
    Dizziness60
    Gastrointestinal disordersDiarrhea63
    Nausea60
    General disorders and administration site conditionsFatigue80
    Malaise60
    InvestigationsWeight decreased60
    Musculoskeletal and connective tissue disordersMuscle spasms80
    Arthralgia63
    Muscle twitching60
    RespiratoryDyspnea60
    Pharyngolaryngeal pain60
    SkinRash80
    Pruritus60

    6.2 Postmarketing Experience

    Adverse reactions have been identified during postapproval use of dichlorphenamide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    The following are adverse reactions which have been reported during postapproval use of dichlorphenamide and were serious or are not reported in the previous section of labeling [see Clinical Trials Experience (6.1)]: amnesia, cardiac failure, condition aggravated, convulsion, hallucination, nephrolithiasis, pancytopenia, psychotic disorder, renal tubular necrosis, stupor, syncope, tremor.

    7 DRUG INTERACTIONS

    7.1 Aspirin and Other Salicylates

    Carbonic anhydrase inhibitors, including KEVEYIS, can cause metabolic acidosis [see Warning and Precautions (5.2, 5.4)], which can increase the risk of salicylate toxicity. Anorexia, tachypnea, lethargy, and coma have been reported with concomitant use of dichlorphenamide and high-dose aspirin. Therefore, concomitant use of KEVEYIS and high-dose aspirin is contraindicated.  Patients with concomitant use of KEVEYIS and low-dose aspirin should be carefully monitored [see Contraindications (4) and Warnings and Precautions (5.2)].

    7.2 Drugs that are Substrates of Organic Anion Transporter1 (OAT1)

    In vitro, dichlorphenamide is an inhibitor of OAT1  transporters. The concomitant administration of KEVEYIS may increase the plasma exposures of OAT1 substrates. Use of KEVEYIS with  drugs that are sensitive to OAT1 inhibition (e.g., methotrexate, famotidine, oseltamivir) is not recommended [see Clinical Pharmacology (12.3)].

    7.3 Drugs that Cause Hypokalemia

    The risk of hypokalemia is greater with coadministration of KEYEVIS and other drugs that can cause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives, antifungals, penicillins, and theophylline) [see Warnings and Precautions (5.3)].

    7.4 Drugs that Cause Metabolic Acidosis

    Coadministration of KEYEVIS and other drugs that can cause metabolic acidosis may increase the severity of the acidosis [see Warnings and Precautions (5.4)].

    7.5 Drugs that are Inhibitors of OAT1 or OAT3

    An In vitro transporter study indicated that dichlorphenamide is a substrate of human transporters OAT1 and OAT3 [see Clinical Pharmacology (12.3)]. Therefore, signs of dichlorphenamide toxicity should be monitored when administered with OAT1 or OAT3 inhibitors.

    8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary
    There are no adequate data on the developmental risk associated with the use of KEVEYIS  in pregnant women. A no-effect dose has not been established. Dichlorphenamide was teratogenic when administered orally to pregnant rats.

    The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4%, and 15% to 20%, respectively.

    Clinical Considerations
    Fetal/Neonatal adverse reactions
    KEVEYIStreatment can cause metabolic acidosis [see Warnings and Precautions (5.4)]. The effect of dichlorphenamide-induced metabolic acidosis has not been studied in pregnancy; however, metabolic acidosis in pregnancy (due to other causes) can cause decreased fetal growth, decreased fetal oxygenation, and fetal death, and may affect the fetus’ ability to tolerate labor. Pregnant patients should be monitored for metabolic acidosis and treated as in the nonpregnant state. Newborns of mothers treated with KEVEYIS should be monitored for metabolic acidosis because of possible occurrence of transient metabolic acidosis following birth.

    Labor or Delivery
    Although the effect of KEVEYIS on labor and delivery in humans has not been established, the development of dichlorphenamide-induced metabolic acidosis in the mother and/or in the fetus might affect the fetus’ ability to tolerate labor. 

    Data
    Animal Data
    Teratogenic effects (fetal limb reduction defects) were reported following oral administration of dichlorphenamide to pregnant rats during organogenesis at 350 mg/kg, or 17 times the maximum recommended human dose (200 mg/day) on a body surface area (mg/m2) basis. A no-effect dose for adverse effects on embryofetal development has not been established.

    8.2 Lactation

    Risk Summary
    There are no data on the presence of dichlorphenamide in human milk, the effects on the breastfed infant, or the effects on milk production. 

    The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for KEVEYIS and any potential adverse effects on the breastfed infant from KEVEYIS or from the underlying maternal condition.

    8.4 Pediatric Use

    Safety and effectiveness of KEVEYIS in pediatric patients have not been established.

    8.5 Geriatric Use

    The risk of falls and of metabolic acidosis are greater in elderly patients. [see Warnings and Precautions (5.4, 5.5)]

    10 OVERDOSAGE

    Symptoms of overdosage or toxicity may include drowsiness, anorexia, nausea, vomiting, dizziness, ataxia, tremor, and tinnitus.

    In the event of overdosage, induce emesis or perform gastric lavage. The electrolyte disturbances most likely to be encountered from overdosage are hypokalemia and hyperchloremic metabolic acidosis.

    11 DESCRIPTION

    KEVEYIS tablets contain dichlorphenamide, an oral carbonic anhydrase inhibitor. Dichlorphenamide, a dichlorinated benzenedisulfonamide, is known chemically as 4, 5–dichloro-1,3-benzenedisulfonamide.

    Its empirical formula is C6H6Cl2N2O4S2 and its structural formula is:

    Chemical Structure

    Dichlorphenamide USP is a white or practically white, crystalline compound with a molecular weight of 305.16. It is very slightly soluble in water but soluble in dilute solutions of sodium carbonate and sodium hydroxide. Dilute alkaline solutions of dichlorphenamide are stable at room temperature.

    KEVEYIS (dichlorphenamide) tablets are supplied as tablets, for oral administration, each containing 50 mg dichlorphenamide. Inactive ingredients are lactose monohydrate, magnesium stearate and pregelatinized starch.

    12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Dichlorphenamide inhibits carbonic anhydrase, an enzyme that controls the rate of inter-conversion of carbon dioxide and water into carbonic acid, protons and bicarbonate ions. However, the precise mechanism by which dichlorphenamide exerts its therapeutic effects in patients with primary periodic paralysis is unknown.

    12.2 Pharmacodynamics

    KEYEVIS can cause metabolic acidosis, which can increase the risk of salicylate toxicity with coadministration [see Warnings and Precautions (5.2)].  KEYEVIS-induced metabolic acidosis can also increase in severity with coadministration of other drugs that cause metabolic acidosis [see Warnings and Precautions (5.4)].

    12.3 Pharmacokinetics

    After single-dose administration in healthy subjects in fasted state, dichlorphenamide Cmax and AUC increased in a dose-proportional manner within the range of 25 mg to 400 mg (2 times the maximum recommended dose). The steady-state is expected to be achieved within 10 days of twice-daily dosing.

    Absorption
    The median time to reach maximum concentration (Tmax) of dichlorphenamide was about 1.5 to 3 hours postdose after both single and multiple dose administrations.

    Distribution
    The plasma protein binding of dichlorphenamide is approximately 88%.

    Elimination
    Following a single-dose administration, mean terminal half-life was in the range of 32 to 66 hours.

    Metabolism
    Dichlorphenamide is not a  substrate for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 isoforms when tested in vitro.

    Drug Interaction Studies

    In vitro Assessment of Drug Interactions

    Drug-Metabolizing Enzyme Inhibition
    Dichlorphenamide is not an inhibitor for CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4 enzymes when tested in vitro.

    Drug-Metabolizing Enzyme Induction
    Dichlorphenamide is not an inducer for CYP1A2, 2B6, or 3A4 enzymes when tested in vitro.

    In vitro Assessment of Transporter-Drug Interactions
    Dichlorphenamide is neither a substrate nor inhibitor for p-gp, BCRP, OATP1B1, OATP1B3, OAT2, OAT4, OCT1, OCT2, MATE1, or MATE2-K when tested in vitro.

    Dichlorphenamide is not an inhibitor of OAT3, but is an inhibitor of OAT1 based on in vitro studies [see Drug Interactions (7.4)].

    Dichlorphenamide is a substrate for transporters OAT1 and OAT3 based on in vitro studies [see Drug Interactions (7.2)]

    In Vivo Drug Interactions
    The use of dichlorphenamide in combination with high-dose aspirin is contraindicated as it may lead to salicylate toxicity. The mechanism(s) of this interaction is not known.

    Specific Populations
    Geriatrics
    The pharmacokinetics of dichlorphenamide in the elderly has not been determined.

    13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenesis

    Studies to assess the carcinogenic potential of dichlorphenamide have not been conducted.

    Mutagenesis

    Studies to assess the genotoxicity of dichlorphenamide have not been conducted.

    Impairment of Fertility

    Studies to assess the effects of dichlorphenamide on fertility have not been conducted.

    14 CLINICAL STUDIES

    The efficacy of KEVEYIS was evaluated in two clinical studies, Study 1 and Study 2.

    Study 1

    Study 1 was a 9-week, double blind, placebo-controlled multi-center study. Study 1 consisted of two substudies: a substudy in patients with hypokalemic periodic paralysis (n=44), and a substudy in patients with hyperkalemic periodic paralysis (n=21). The primary efficacy endpoint in both substudies was the average number of self-reported attacks of muscle weakness per week over the final 8 weeks of the trial. Withdrawal from the study for acute severe worsening (increase in attack frequency or severity) was also assessed as an endpoint.

    In Study 1, the dose of KEVEYIS was 50 mg b.i.d. for treatment-naïve patients. Patients already on dichlorphenamide prior to the study continued on the same dose while on KEVEYIS during the study. In patients taking acetazolamide prior to the study, the dose of KEVEYIS was set at 20% of the acetazolamide dose. Dose reduction for tolerability was permitted.

    Hypokalemic Periodic Paralysis Substudy of Study 1

    In the hypokalemic periodic paralysis substudy, median age of patients was 45 years and 73% of patients were male. Patients treated with KEVEYIS (n=24) had 2.2 fewer attacks per week than patients (n=20) treated with placebo (p=0.02). None of the patients randomized to KEVEYIS reached the endpoint of withdrawal from the study for acute worsening, vs. five patients randomized to placebo. The mean dose of KEVEYIS at Week 9 was 94 mg/day.

    Hyperkalemic Periodic Paralysis Substudy of Study 1

    In the Hyperkalemic Periodic Paralysis substudy, median age of patients was 43 years and 43% of patients were male. During the double-blind treatment period, patients treated with KEVEYIS (n=12) had 3.9 fewer attacks per week than patients (n=9) treated with placebo (p=0.08). None of the patients randomized to KEVEYIS reached the endpoint of withdrawal from the study for acute worsening, vs. two patients randomized to placebo. The mean dose of KEVEYIS at Week 9 was 82 mg/day.

    Study 2

    Study 2 was a 35-week, double blind, placebo-controlled, multi-center, two-period crossover study. Study 2 also consisted of two substudies: a substudy in patients with hypokalemic periodic paralysis (n=42), and a substudy in patients with hyperkalemic periodic paralysis (n=31), including patients with Paramyotonia Congenita. The primary endpoint in the hypokalemic periodic paralysis substudy was the incidence of acute intolerable worsening (based on attack frequency or severity) necessitating withdrawal. The primary endpoint in the hyperkalemic periodic paralysis substudy was the average number of self-reported attacks of muscle weakness per week. Dosing was determined similarly to Study 1.

    Hypokalemic Periodic Paralysis Substudy of Study 2

    The hypokalemic periodic paralysis substudy included patients with a mean age of 38 years; 79% of patients were male. Acute intolerable worsening was observed in 2 patients on KEVEYIS vs. 11 patients on placebo (p=0.02). The mean dose of KEVEYIS at the end of the study was 96 mg/day.

    Hyperkalemic Periodic Paralysis Substudy of Study 2

    The hyperkalemic periodic paralysis substudy included patients with a mean age of 37 years; and 79% of patients were male. Patients treated had 2.3 fewer attacks per week on KEVEYIS than on placebo (p=0.006). The mean dose of KEVEYIS at the end of the study was 73 mg/day.

    16 HOW SUPPLIED/STORAGE AND HANDLING

    Each KEVEYIS (dichlorphenamide) tablet, 50 mg is round, white, scored on one side, engraved with "D" above the score and "50" below the score. The other side is plain.

    KEVEYIS (dichlorphenamide) tablets are supplied as follows:

    Bottles of 100......................................NDC: 71090-001-01

    Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature].

    17 PATIENT COUNSELING INFORMATION

    Worsening of Symptoms
    Advise patients to notify their physician if they experience acute worsening of symptoms of periodic paralysis.

    Hypersensitivity and Other Life-Threatening Reactions
    Inform patients that hypersensitivity and immune mediated reactions can occur with KEVEYIS, and could be fatal.  Advise patients to discontinue KEVEYIS and notify their healthcare provider immediately if they develop a rash or signs and symptoms of anaphylaxis or other life-threatening reactions [see Warnings and Precautions (5.1)].

    Drug Interactions
    Instruct patients to notify their healthcare provider of all of the drugs and over-the-counter medications that they take and to not take aspirin or other salicylates without first discussing with their healthcare provider [see Drug Interactions (7.1, 7.2, 7.3, 7.4)].

    Metabolic Acidosis
    Instruct patients to contact their healthcare provider immediately if they develop possible manifestations of metabolic acidosis (e.g., fast breathing, fatigue/tiredness, loss of appetite, or irregular heart beat or palpitations) [see Warnings and Precautions (5.4)].

    Falls
    Inform patients that KEYEVIS can increase their risk of falls [see Warnings and Precautions (5.5)].

    Cognitive Impairment
    Advise patients to notify their healthcare provider if they experience symptoms of cognitive impairment including confusion and memory lapse [see Adverse Reactions (6.1)].

    Driving and Operating Machinery
    KEVEYIS may cause drowsiness/fatigue in some patients [see Adverse Reactions (6.1)]. Caution patients on the potential for impaired ability to drive and operate machinery.

    Manufactured by:  Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761
    Distributed by:  Strongbridge US Inc., Trevose, PA 19053

    KEVEYIS® is a registered trademark licensed exclusively in the US to Strongbridge Biopharma plc.

    STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which includes Strongbridge Dublin Limited and Strongbridge U.S. Inc.

    21061-0117-0

    STRONGBRIDGE BIOPHARMA

    PRINCIPAL DISPLAY PANEL - 50 mg Tablet Bottle Label

    NDC: 71090-001-01
    100 Tablets

    Keveyis®
    (dichlorphenamide)
    Tablets 50 mg

    Keep this and all medications out
    of the reach of children.

    Rx only

    PRINCIPAL DISPLAY PANEL - 50 mg Tablet Bottle Label
    KEVEYIS 
    dichlorphenamide tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 71090-001
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Dichlorphenamide (UNII: VVJ6673MHY) (Dichlorphenamide - UNII:VVJ6673MHY) Dichlorphenamide50 mg
    Inactive Ingredients
    Ingredient NameStrength
    lactose monohydrate (UNII: EWQ57Q8I5X)  
    magnesium stearate (UNII: 70097M6I30)  
    starch, corn (UNII: O8232NY3SJ)  
    Product Characteristics
    ColorWHITEScore2 pieces
    ShapeROUNDSize6mm
    FlavorImprint Code D;50
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 71090-001-01100 in 1 BOTTLE; Type 0: Not a Combination Product02/21/2017
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01136608/07/2015
    Labeler - Strongbridge US Inc. (080121041)

    Revised: 11/2019
     
    Strongbridge US Inc.


    © 2019 FDA.report
    This site is not affiliated with or endorsed by the FDA.